Share on LinkedInShare on LinkedIn

ARTICLE · 16 NOVEMBER 2016

CETA Implementation In Canada: Bill C-30 Brings Significant Changes To The Canadian Patent System

McCarthy Tétrault
McCarthy Tétrault
Contributor
McCarthy Tétrault

McCarthy Tétrault

Built on a unique model of collaboration, innovation and efficiency, McCarthy Tétrault delivers...

View firm profile
Explore more from McCarthy Tétrault

Changes are coming swiftly, as the federal government moves to implement the Comprehensive Economic and Trade Agreement...

CanadaIntellectual Property

Changes are coming swiftly, as the federal government moves to implement the Comprehensive Economic and Trade Agreement ("CETA") just days after it was signed by Prime Minister Trudeau in Brussels at the end of October 2016.

These changes will significantly impact biologic/pharma patents in two major ways. First, they will implement, for the first time, a Canadianized version of patent-term restoration. Second, they will revamp the current framework for linkage between patents and the approval of biosimilar/generic drugs in Canada by giving innovators the right of appeal, by changing the nature of the PM(NOC) proceedings to a more U.S.-style approach, and by providing for finality in such litigation.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from